الفهرس 
acknowledgmentOnly 14 pages are availabe for public view
 |  | from | 121 |  |  |
| | | from | 121 | | |
Abstract
Melatonin, the endogenous signal of darkness, is an important component of our body’s internal timekeeping system. Additionally, Melatonin participates in many other physiological functions being an effective antioxidant, immune enhancing, and cytoprotective agent. Melatonin receptor 2 (MTNR1B) is one of the two characterized mammalian G coupled receptors for Melatonin to work on. A common Single Nucleotide Polymorphism (SNP) among the MTNR1B gene is (rs#l 0830963), which is well known for causing Type 2 Diabetes (T2D) high incidence risk. We evaluated the association of MTNR1B gene polymorphism (rs#10830963) with breast cancer incidence in 43 breast cancer female patients and 45 healthy female control group. Restriction Fragment Length Polymorphism (RFLP) PCR was used for the analysis of MTNR1B gene polymorphism (rs#10830963) using the peripheral blood of all cases and controls. Besides, Melatonin hormone level in the serum of all subjects enrolled in this study was measured using a ready-for-use Radio-Immuno Assay (RIA) kit.
Results showed that the (GG) genotype frequency was significantly increased among the breast cancer cases rather than its frequency among controls. Up to this moment and to our best knowledge, no other reports are published correlating the MTNR1B gene SNP (rs#10830963) and breast cancer incidence. Furthermore, the Melatonin hormone level was found to be significantly lower in breast cancer patients’ serum comparing with that of the control group of this study. Also, the GG genotypes were significantly associated with larger tumor volume (cm3) and higher number of malignant axillary lymph nodes among the breast cancer patients. To conclude, we suggest the association of these Melatonin signaling pathway alterations with breast cancer incidence among the Egyptian females.
Keywords: Melatonin, MTNR1B, rs# 10830963, Breast Cancer.